| 51.89 2.785 (5.67%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.47 | 1-year : | 69.14 |
| Resists | First : | 54.34 | Second : | 59.2 |
| Pivot price | 50.13  |
|||
| Supports | First : | 46.5 | Second : | 38.68 |
| MAs | MA(5) : | 49.29 |
MA(20) : | 50.48 |
| MA(100) : | 61.57 |
MA(250) : | 126.66 |
|
| MACD | MACD : | -1.9 |
Signal : | -2.2 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 23.2 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 838.12 | Low : | 7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SPRB ] has closed below upper band by 20.3%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 53.34 - 53.6 | 53.6 - 53.83 |
| Low: | 48.42 - 48.71 | 48.71 - 48.96 |
| Close: | 51.41 - 51.89 | 51.89 - 52.33 |
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Tue, 09 Jun 2026
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Mon, 08 Jun 2026
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Mon, 08 Jun 2026
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Wed, 27 May 2026
Spruce Biosciences to Participate in Upcoming Conferences in June - Investing News Network
Tue, 26 May 2026
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 31 (%) |
| Shares Short | 215 (K) |
| Shares Short P.Month | 181 (K) |
| EPS | -35.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.2 % |
| Return on Equity (ttm) | -148.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.96 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -1.45 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|